# Cizzle Biotechnology’s Allan Syms on new MoU for North America, revenue streams and market expansion (LON:CIZ)

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnologys-allan-syms-on-new-mou-for-north-america-revenue-streams-and-market-expansion-lonciz/4121152008
- Published: 2024-04-16T13:13:52+01:00
- Author: Amilia Stone

**Cizzle Biotechnology plc (LON:CIZ)** Executive Chairman Allan Syms caught up with
DirectorsTalk for an exclusive interview to discuss the new Licensing and Partnership
MoU for North America, why the focus on North America, royalties & financial return
on sales, development plans and the routes to market for the test outside of the
USA, key milestones & targets, and the steps to bring the product formats to market.

**Q1: Alan, you’ve announced an MOU covering a new proposed licensing and partnership
agreement to cover the group’s activities in the US. Could you just give us an overview
of what’s envisaged there?**

**A1**: Well first off, absolutely delighted to have finally got this agreement 
together,  somewhat we’ve been negotiating for a while, and it falls nicely after
our last announcement of raising money to largely be putting into clinical trials.
We do see the United States as such an important market and so we were very keen
to actually have a presence there in the USA and to date, that has been through 
our partnership with Corepath Laboratories.

This takes us to a completely different level.

So, this is setting up an entity in the United States that is fully funded from 
the USA by high net worth individuals which means that we as a company are not going
to be putting money into the USA, this is all going to be covered by the investors
in the US.

What it means for the company is that we’re getting a guaranteed royalty stream 
in total with upfront payments of $2.4 million, and that means a lot to us. We’re
a company that’s small, we have low overheads so bringing $2.4 million into the 
company over a period of 30 months is a substantial revenue stream to bring into
the company. In addition to that, we get a free carry in the business in the USA
so the revenues won’t just stop there, in addition to that, we will have a share
of the business and the proceeds and revenues that that business will generate.

On top of that, as I said already, we had previously budgeted to do this ourselves,
that’s the reason why we did the announcement only last week to actually cover what
we needed, what we believed were going to be the cost of doing those clinical trials.
Now, we don’t have to do that. That’s effectively a saving of nearly £500,000 for
the company.

So, in total we’re bringing in $2.4 million guaranteed revenues, we have a share
of the business in the United States and we are going to get further savings because
we’re not having to spend the money that we’ve got on our own. The way we envisage
the relationship working is that the business in the USA will continue to support
some of the development work in the UK as well, which means at the end of the day
I think we will also see monies flowing to further development of our product stream
in the UK.

So, a tremendous deal, revenue generating, bringing us with a very low overhead 
business into what I believe shareholders are really seeking, which is can we see
when the revenue is going to arrive for the company and lessen our dependence upon
shareholder funding to keep the business in the direction we want it to go.

So yes, absolutely delighted with the result of this.

**Q2: So, the new Cizzle Bio Inc intends to conduct clinical trials amongst other
things and commercialise the group’s early stage lung cancer test in the USA. Could
you explain why you’re going down that route and focusing on the USA at this stage
and not just doing the work itself and having 100% of the benefit?**

**A2**: Great question and several elements to it.

Why the USA? Well, because it’s a huge marketplace, right now there is a preventative
task force looking at lung cancer screening in the USA and they’re demanding that
they go out, find targeted groups and test over 14 million people a year in the 
USA. Unfortunately, the methodology for that is using CT scanning and for socioeconomic
reasons and also because people are heavily dependent upon medical insurance in 
the US, that is not really something that’s available to them. So, there’s very 
low take-up and so there’s a really big unmet need in the USA for a very simple 
blood test like the test that we are developing.

So number one, the USA is very important.

Second part of your question was, why aren’t we doing this ourselves because potentially,
there are very large margins in doing this assay. The simple answer is, we’re a 
licensing business. For us to set up on our own in the USA, we would have to invest
very substantial sums of money in infrastructure, wet lab facilities of our own,
that also takes time to do. In addition to that, there are various accreditations
and rules that go around using a clinical laboratory to do these testing and most
importantly, the people, we would have to hire a workforce in North America.

So, in the end, it’s the time it takes to do this, primarily it’s the cost associated
with putting up the infrastructure, and together with the regulatory things means
we would be a very long way down the road before we’re actually able to do this 
ourselves. We’re a small virtual business with a licensing strategy and this is 
part of that licensing strategy.

**Q3: Now, there were royalties outlined in the announcement. Am I right in thinking
that these are minimum guaranteed payments and that the financial return for sales
could be much larger from the US venture?**

**A3**: Yes, absolutely, let me break that down a little bit, a little bit about
the way that which the money comes and the way the structure is.

Our arrangement is for a 10% royalty stream and I also want to emphasise that we’re
incorporating our existing deal that we have with Corepath Laboratories, who are
one of those great labs that are specialists in oncology. They have their own infrastructure
and people and accreditation so we’re rolling this all in together, and in the end,
we will end up with a net 10% royalty on all sales that come from North America.
So, from our viewpoint, that isn’t limited to the minimums.

The reason there are minimums there is because this is an exclusive license to North
America and most people who have done licensing deals, and I’ve done many licensing
deals in my time, would always seek to have some guarantee of revenues. If you’re
giving a territory, such an important territory as North America, you would seek
minimum payments and that’s what those payments are, those are the minimums we expect
to get, but they’re certainly not the maximum by any shape or form. It is definitely
the minimum which we will then get, as we exceed those minimum levels, we will then
benefit from full 10%. Don’t forget, of course, we’ve got a 10% equity share in 
the business.

So we’re getting, if you like, a bite on both parts of that particular cherry for
us. So that’s why it’s so very exciting.

**Q4: Now the planned venture obviously just covers the USA. What does that mean
for sales activities in the UK and the rest of the world, specifically the development
plans and the routes to market for the test outside of the USA?**

**A4**: Well, let’s just clarify, it’s North America, so it’s not just the USA, 
it’s Canada as well. It makes sense, the trading relationship between Canada and
the United States is so close, it will be crazy for us not to include Canada. So,
this deal is for all of North America in the first instance.

I think the second thing is, I’ve mentioned what we get in terms of our revenue 
streams, our partnership from this entity being in North America but we do envisage
there to be a lot of improvements. We envisage that obviously the clinical trials
work will have been done and obviously the product formats, and I’m going to tell
you a little bit more about the product formats towards the end of this particular
interview, because I think it’s important for everyone and our shareholders to understand
we’re not a one-trick pony. We’re not just a single product, we have multiple potential
products.

All of those inventions and all of those potential developments will come back to
the business in the UK, which means we have rights to the rest of the world. So,
all of that investment that’s going on in North America, there will be a further
additional benefit that we will own those rights for our strategies in China, for
putting things in place in the rest of Asia-Pac, and most importantly, Europe and
in the UK.

**Q5: Just to finish though, and I know you want to go on and explain, but could
you just summarise what you see as the key milestones and targets for Cizzle Technology
over the short to medium term?**

**A5**: I think that’s the great segue into what I was just saying is that, and 
I’d like to take the opportunity to all of our shareholders to just say, look, sometimes
these things seem quite complex, and we will improve our communication regularity
with shareholders to help explain the differences between different product formats.

It’s important that, as I said, we’re not just looking at a single product, our 
first commercial test is, as we have said in the marketplace, to be done in a laboratory,
we are working still closely with Bio-Techne, and we have a number of different 
monoclonal antibodies that are relevant to different product formats.

So, the first commercial test will be for that laboratory test using the system 
that we’ve been working with for quite a while now and complete the clinical trials
on that. I also see that there will be further test formats, there is a test called
an ELISA format, for example, and basically that’s a 96-well plastic dish where 
everybody puts their various samples and washing steps and antibodies, it’s still
a lab-based test, but it’s really meant for mass-scale testing. Ultimately, the 
vision is for something that can be used in doctors’ offices and pharmacies, a bit
like akin to a fingerprint test that you would see for somebody with diabetes, and
then using a lateral flow device that, for example, has been used so well for pregnancy
testing and more later, of course, for COVID.

So, there are these different product formats so the way in which we see the company
moving forward is that we will deliver on each of these different formats. That 
requires different antibodies with different conditions of doing the test and that’s
why I wanted to clarify to our shareholders the recent announcement we made about
a further monoclonal antibody. It’s not that our other ones don’t work, it’s just
that we need different antibodies for different product formats and so, that’s why
it’s very important for us to have these three different formats to go forward with.

Each one of them will require different clinical trials, each one will require different
sets of conditions, each probably will need their own particular monoclonal antibody,
all of that’s proprietary to the company.

So, those are the key things going forward that we need to consider.

**Q6: Just before we go, could you just explain for us, for these product formats,
what are the steps to bring these products to market?**

**A6**: Yes, really down into the detail, that’s very important, something that 
we want shareholders to have a good understanding of, which is that there are very
clearly defined milestones that the company has set itself to achieve a product 
that goes to market. We have said this before, but this is a great opportunity just
to explain that in more detail.

The first thing is we now need to go into a commercial manufacturing mode. Everything
we’ve done thus far has been done with the great laboratories that we have at the
University of York with Professor Dawn Coverley, the founder but now we’re into 
that commercial drive to get first product to market. So, the first thing is we 
need our antibodies to be manufactured by a third party and we will make some announcements
about that fairly soon, about who is manufacturing and to what quality management
system are those antibodies made.

Those antibodies are then used for the clinical trials that are actually then the
basis of the commercial test. So, we do lots of clinical tests, we’ve done over 
the years many clinical tests to validate the technology but each time you’re going
to put a product into the market, that particular product format needs to be retested
in a clinical trial setting. So, those commercial antibodies will be used for doing
those clinical trials.

You then have to have that accredited, and whether that’s accredited as a laboratory-
developed test within a laboratory or goes on to become approved by the FDA as an
FDA 510(k) product or in Europe through a CE mark or in the UK as a UK CA mark.

Then it is, well, who’s going to pay for that? Of course, since our prime market
is the USA currently, that means getting into the reimbursement area so we need 
reimbursement codes, we need to understand the way in which this product will be
paid for by Medicare and other insurance companies.

So, four fairly delineated steps now, and we will come back to shareholders and 
report on progress on every single one of those as we go.

Share on:
